Table 2—

Total and individual symptom scores after 12 weeks of treatment

ParameterTreatmentMeanDifference relative to placebo
%95% CIp-value
Sleep disturbanceFormoterol 4.5 µg1.6499.3293.39–105.620.8271
Formoterol 9 µg1.66100.6094.51–107.080.8506
Formoterol 18 µg1.5694.2988.71–100.220.0588
Placebo1.65
BreathlessnessFormoterol 4.5 µg2.2996.7591.13–102.720.2784
Formoterol 9 µg2.1992.6587.20–98.440.0136
Formoterol 18 µg2.1590.7685.53–96.310.0014
Placebo2.37
CoughFormoterol 4.5 µg2.0196.6490.75–102.910.2864
Formoterol 9 µg2.0397.7891.73–104.230.4905
Formoterol 18 µg2.0397.5791.67–103.850.4391
Placebo2.08
Chest tightnessFormoterol 4.5 µg1.8196.5690.59–102.930.2822
Formoterol 9 µg1.6688.9883.40–94.930.0004
Formoterol 18 µg1.7291.9986.35–98.010.0099
Placebo1.87
Total symptom score#Formoterol 4.5 µg4.6894.0586.23–102.580.1660
Formoterol 9 µg4.5892.1684.39–100.640.0691
Formoterol 18 µg4.3487.2580.06–95.090.0019
Placebo4.97
  • Data are presented as adjusted geometric means unless otherwise stated

  • CI: confidence interval

  • #: adjusted geometric means calculated from the multiplicative analysis of the average total symptom score